RxDoctor Payments Data

David Philips, MD

Interventional Cardiology · Camas, WANPI 1629040480

Payments from drug & device makers

$3,955in general payments, 2019–2025

Across 33 payments — averaging $119.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$732
  • Abbott$182
  • Novartis$104
  • Actelion Pharmaceuticals US, Inc.$37
  • Edwards Lifesciences$27
  • plus $63 from 3 others

What the payments were for

  • Travel & lodging$3,11479%
  • Food & beverage$84221%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,955 in reported general payments places this provider in the 45th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$223,411
Medicare patients
2,249
Services billed
3,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$110,855
XareltoRivaroxaban48$42,819
EntrestoSacubitril/Valsartan34$41,254
BrilintaTicagrelor19$17,305
Atorvastatin Calcium286$4,126
Metoprolol Succinate238$3,546
ClopidogrelClopidogrel Bisulfate146$2,034
Flecainide Acetate25$1,443
Rosuvastatin Calcium66$1,128
Losartan Potassium119$1,120
Isosorbide Mononitrate ErIsosorbide Mononitrate67$700
Carvedilol89$630
Spironolactone52$602
Ezetimibe16$599
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$104$41,25434 claims
AstraZenecaBrilinta$15$17,30519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Camas

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →